Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery

References

• Lindstrom R Thoughts on cataract surgery: 2015: review of opthalmology; 2015 cited 2018 Sep 20. Available from: https://www.reviewofophthalmology.com/article/thoughts-on–cataract-surgery-2015
   Google Scholar
• Benitah NR, Arroyo JG. Pseudophakic cystoid macular edema. Int Ophthalmol Clin. 2010 Winter;50(1):139–153.
   PubMedGoogle Scholar
• Gass JD, Norton EW. Cystoid macular edema and papilledema following cataract extraction. A fluorescein fundoscopic and angiographic study. Arch Ophthalmol. 1966 Nov;76(5):646–661.
   PubMedGoogle Scholar
• Gass JD, Norton EW. Fluorescein studies of patients with macular edema and papilledema following cataract extraction. Trans Am Ophthalmol Soc. 1966;64:232–249.
   PubMedGoogle Scholar
• Irvine SR. A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol. 1953 May;36(5):599–619.
   PubMed Web of Science ®Google Scholar
• NDA 206911 1.14.2.3 Final Labeling Text. FDA.gov: FDA; 2016. p. 2–3.
   Google Scholar
• Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133–1140.
   PubMed Web of Science ®Google Scholar
• Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. Faseb J. 1998 Sep;12(12):1063–1073.
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Kulkarni PS. Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation. Surv Ophthalmol. 1997 Feb;41(Suppl 2):S35–40.
   PubMed Web of Science ®Google Scholar
• Robinson DR. Prostaglandins and the mechanism of action of anti-inflammatory drugs. Am J Med. 1983 Oct 31;75:(4b):26–31.
   Web of Science ®Google Scholar
• Abel R Jr., Abel AD. Perioperative antibiotic, steroidal, and nonsteroidal anti-inflammatory agents in cataract intraocular lens surgery. Curr Opin Ophthalmol. 1996 Feb;7(1):39–42.
   PubMedGoogle Scholar
• Ahuja M, Dhake AS, Sharma SK, et al. Topical ocular delivery of NSAIDs. Aaps J. 2008 Jun;10(2):229–241.
   PubMed Web of Science ®Google Scholar
• Colin J. The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs. 2007;67(9):1291–1308.
   PubMed Web of Science ®Google Scholar
• Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmol J Int D’ophtalmologie Int J Ophthalmol Zeitschrift Fur Augenheilkunde. 2003 Mar–Apr;217(2):89–98.
   Web of Science ®Google Scholar
• Bowling B. Kanski’s clinical ophthalmology: a systematic approach. 8th ed. London, England: Elsevier; 2016. p. 254.
   Google Scholar
• Chad Lesczynski P. In: Scott Wentz M, editor; 2018.
   Google Scholar
• Friedlaender MH, Protzko E. Clinical development of 1% azithromycin in duraSite, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol. 2007 Mar;1(1):3–10.
   PubMedGoogle Scholar
• BromSite(TM) (bromfenac ophthalmic solution) 0.075% bromsite website cited 2018 May 28. Available from: https://www.bromsite.com
   Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005 Sep;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Malik A, Sadafale A, Gupta YK, et al. A comparative study of various topical nonsteroidal anti-inflammatory drugs to steroid drops for control of post cataract surgery inflammation. Oman J Ophthalmol. 2016 Sep-Dec;9(3):150–156.
   PubMedGoogle Scholar
• Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011 May;31(5):986–1000.
   PubMed Web of Science ®Google Scholar
• Duan P, Liu Y, Li J. The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2017 Apr;255(4):639–649.
   PubMed Web of Science ®Google Scholar
• Si EC, Bowman LM, Hosseini K. Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom. J Ocular Pharmacol Ther. 2011 Feb;27(1):61–66.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Cockrum PC, Justice A, et al. In vivo pharmacokinetics of bromfenac ophthalmic solution 0.075%, bromfenac ophthalmic solution 0.07%, and nepafenac/amfenac ophthalmic suspension 0.3% in rabbits. Ophthalmol Ther. 2018 May 14;7:157–165.
   PubMed Web of Science ®Google Scholar
• Trattler W, Hosseini K. Twice-daily vs. once-daily dosing with 0.075% bromfenac in DuraSite: outcomes from a 14-day phase 2 study. Ophthalmol Ther. 2017 Dec;6(2):277–284.
   PubMed Web of Science ®Google Scholar
• Hosseini K, Walters T, DaVanzo R, et al. A randomized double-masked study to compare the ocular safety, tolerability, and efficacy of bromfenac 0.075% compared with vehicle in cataract surgery subjects. Clin Ophthalmol. 2016;10:2311–2317.
   PubMed Web of Science ®Google Scholar
• Almeida DR, Johnson D, Hollands H, et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J Cataract Refract Surg. 2008 Jan;34(1):64–69.
   PubMed Web of Science ®Google Scholar
• Wittpenn JR, Silverstein S, Heier J, et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008 Oct;146(4):554–560.
   PubMed Web of Science ®Google Scholar
• Asano S, Miyake K, Ota I, et al. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. J Cataract Refract Surg. 2008 Jan;34(1):57–63.
   PubMed Web of Science ®Google Scholar
• Wielders LHP, Schouten J, Winkens B, et al. European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. J Cataract Refract Surg. 2018 Apr;44(4):429–439.
   PubMed Web of Science ®Google Scholar
• Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000 Nov;107(11):2034–2038. discussion 2039.
   PubMed Web of Science ®Google Scholar
• Kim CY, Park KH, Ahn J, et al. Treatment patterns and medication adherence of patients with glaucoma in South Korea. Br J Ophthalmol. 2017;101(6):801–807.
   PubMed Web of Science ®Google Scholar
• Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997 Oct;20(10):1512–1517.
   PubMed Web of Science ®Google Scholar
• Bowman LM, Si E, Pang J, et al. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J Ocular Pharmacol Therapeut. 2009 Apr;25(2):133–139.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos C, Tsapardoni F, Makri O. Effect of bromfenac on pain related to intravitreal injections: a randomized crossover study. Retina. 2017;37(2):388–395.
   PubMed Web of Science ®Google Scholar
• Cleaveland NA, De Mann DW, Carlson NE, et al. Efficacy and perioperative timing of bromfenac in the management of ocular discomfort after femtosecond laser–assisted laser in situ keratomileusis. J Cataract Refract Surg. 2017;43(2):183–188.
   PubMed Web of Science ®Google Scholar
• NSAID UPDATE. American society of cataract and refractive surgery; 1999.
   Google Scholar
• Hargrave SL, Jung JC, Fini ME, et al. Possible role of the vitamin E solubilizer in topical diclofenac on matrix metalloproteinase expression in corneal melting: an analysis of postoperative keratolysis. Ophthalmology. 2002 Feb;109(2):343–350.
   PubMed Web of Science ®Google Scholar
• McIntyre BS, Briski KP, Gapor A, et al. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med. 2000 Sep;224(4):292–301.
   PubMed Web of Science ®Google Scholar
• Price FW. New pieces for the puzzle: nonsteroidal anti-inflammatory drugs and corneal ulcers. J Cataract Refract Surg. 2000 Sep;26(9):1263–1265.
   PubMed Web of Science ®Google Scholar
• Simmons DL, Botting RM, Robertson PM, et al. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3275–3280.
   PubMed Web of Science ®Google Scholar
• Donnenfeld E, Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin. 2006;46(4):21–40.
   PubMedGoogle Scholar
• Asai T, Nakagami T, Mochizuki M, et al. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea. 2006 Feb;25(2):224–227.
   PubMed Web of Science ®Google Scholar
• Maguire J, CJ R, IJ U. Topical NSAIDs: best Practices for Safe Use. In: Burling-Phillips L, editor. American Academy of Ophthalmology; 2013. [cited 2019 Jan]. Available from: https://www.aao.org/eyenet/article/topical-nsaids-best-practices-safe-use?july-2013
   Google Scholar
• Walters TR. An ex vivo human aqueous humor-concentration comparison of two commercial bromfenac formulations. Clin Ophthalmol. 2018;12:943–947.
   Google Scholar
• Panara MR, Renda G, Sciulli MG, et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276–280.
   PubMed Web of Science ®Google Scholar
• Bromfenac: drug Information - UpToDate. US: Pricing. cited 2018 May 28. Available from: https://www.uptodate.com/contents/bromfenac-drug-information?search=bromfenac&source=search_result&selectedTitle=1~5&usage_type=default&display_rank=1#F518366
   Google Scholar
• Belair ML, Kim SJ, Thorne JE, et al. Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am J Ophthalmol. 2009 Jul;148(1):128–35.e2.
   PubMed Web of Science ®Google Scholar
• BA H, JY K, CS A, et al. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007 Sep;33(9):1550–1558.
   PubMed Web of Science ®Google Scholar
• Opitz DL, Harthan JS. Review of azithromycin ophthalmic 1% solution (AzaSite(®)) for the treatment of ocular infections. Ophthalmol Eye Dis. 2012;4:1–14.
   PubMedGoogle Scholar